Heatwurx Inc.
PCSA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.0% and free cash flow grew 20.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PCSA
Heatwurx Inc. (PCSA) EV/Sales
As of 22 October 2026, Heatwurx Inc. (PCSA) trades at a EV/Sales of 48.4×. Over the past ten years it has ranged from −28.9× (May 2024) to 2,590× (March 2015); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 9.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2015 | 41.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2016 | 26.2× | (36.37%) |
| Dec 2015 | 41.2× | 3.62% |
| Sep 2015 | 39.8× | (48.03%) |
| Mar 2015 | 76.6× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −348× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | −38.1× |
| LGVN Longeveron Inc. compare | −3.6× |
| XBIO Xenetic Biosciences, Inc. compare | −0.3× |
| JAGX Jaguar Animal Health, Inc. compare | −0.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PCSA Heatwurx Inc. | 48.4× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)